Evicenter
P&T meetings

Emcitate (tiratricol)

MCT8 deficiency

Last updated
78 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Care management intervention strategies

4 evidence topics · 3 sources

Monitoring guideline: development process and evidence basis

“The recommendations presented in this manuscript were developed during a virtual advisory board meeting on 26 November 2024, facilitated by Egetis Therapeutics.” (opens the source at this quote in a new tab)

“MCT8 deficiency is a rare disease, and the available evidence supporting these recommendations is limited and has not been assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.” (opens the source at this quote in a new tab)

Clinical lead and multidisciplinary coordination

“Patients require lifelong, coordinated, and cohesive multidisciplinary care tailored to their specific clinical presentation.” (opens the source at this quote in a new tab)

“A clinical lead should be assigned for each patient who is newly diagnosed with MCT8 deficiency. The appointment of this lead will depend on local circumstances and, in most cases, will be an endocrinologist or neurologist.” (opens the source at this quote in a new tab)

“Family members and caregivers should be referred for support with social pediatric issues: psychological counseling for parents or siblings may also be warranted, depending on individual needs.” (opens the source at this quote in a new tab)

Family support, care coordination, and palliative care

“Ensure appropriate social work involvement to connect families w/local resources, respite, & support.” (opens the source at this quote in a new tab)

“Coordinate care to manage multiple subspecialty appointments, equipment, medications, & supplies.” (opens the source at this quote in a new tab)

“Ongoing assessment of need for palliative care involvement &/or home nursing” (opens the source at this quote in a new tab)

Patient and caregiver counseling on thyrotoxicosis and abrupt discontinuation

“Advise patients to report signs and symptoms of thyrotoxicosis (such as hyperhidrosis, irritability, insomnia, nightmares, increases in heart rate and elevations in systolic blood pressure, or diarrhea) that occur for the first time or worsen during treatment” (opens the prescribing information at this quote)

“Inform patients and/or caregivers not to stop taking EMCITATE abruptly or without first checking with their healthcare providers as there will be a need for gradual dose reductions to decrease the risk of thyrotoxic symptoms and signs.” (opens the prescribing information at this quote)